-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Carlsmed, Raises Price Target to $20

Benzinga·08/06/2026 15:53:43
Listen to the news
Truist Securities analyst Richard Newitter maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $18 to $20.